Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales

Incyte Corporation (NASDAQ:INCY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 10, Incyte Corporation reported that the company’s Q4 2025 revenue climbed 28% to $1.51 billion, while full-year sales reached $5.14 billion. The company’s growth was largely propelled by its flagship product, Jakafi, which achieved annual sales of $3.093 billion, and the rapid expansion of Opzelura in the atopic dermatitis and vitiligo markets.

The company’s core business, excluding Jakafi, grew by 53% year-over-year in the final quarter. Key contributors included the hematology and oncology franchise, featuring Niktimvo and Monjuvi, which saw a 121% quarterly revenue surge. Incyte’s R&D efforts also reached a new level of maturity in 2025, with timely regulatory submissions for Jakafi XR and povercinib. Management expects this momentum to continue into 2026, forecasting core business growth of over 30% as the company moves towards a goal of 14 pivotal clinical trials by year-end.

Incyte Corporation (NASDAQ:INCY) now aims to nearly double its business size through a combination of internal innovation and strategic business development. While the company anticipates a mid-single-digit sales increase for Jakafi in 2026, it is heavily investing in next-gen treatments, such as its KRAS program and frontline DLBCL therapies.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the US, Europe, Canada, and Japan. The company has collaboration and license agreements with Novartis, Lilly, and Syndax.